MAYNE PHARMA, INC. – Trademark Portfolio
Entity Type: 03
MAYNE PHARMA, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ESGIC and ZEBUTAL. The owner is based in GREENVILLE, NC.
1240 SUGG PARKWAY
GREENVILLE, NC 27834
Showing of trademarks Trademarks
Trademark Classifications
MAYNE PHARMA, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does MAYNE PHARMA, INC. have?
MAYNE PHARMA, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 7 cancelled.
What trademark classes does MAYNE PHARMA, INC. file in?
MAYNE PHARMA, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 45 (Legal & Security Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are MAYNE PHARMA, INC.'s most well-known trademarks?
MAYNE PHARMA, INC.'s registered trademark portfolio includes well-known marks such as ESGIC and ZEBUTAL. These are among 2 currently registered trademarks in the portfolio.
What is MAYNE PHARMA, INC.'s trademark registration success rate?
MAYNE PHARMA, INC. has a 20% trademark registration rate, with 2 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.